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Superoxide anion (O
2
∙−) is overproduced in joint inflammation, rheumatoid arthritis, and osteoarthritis. Increased O
2
∙−
production leads to tissue damage, articular degeneration, and pain. In these conditions, the physiological defense against O
2
∙−,
superoxide dismutases (SOD) are decreased. The MnII complex MnL4 is a potent SOD mimetic, and in this study it was tested in
inflammatory and osteoarticular rat painmodels. In vivoprotocolswere approved by the animal Ethical Committee of theUniversity
of Florence. Pain was measured by paw pressure and hind limb weight bearing alterations tests. MnL4 (15mg kg−1) acutely
administered, significantly reduced pain induced by carrageenan, complete Freund’s adjuvant (CFA), and sodiummonoiodoacetate
(MIA). InCFAandMIAprotocols, it ameliorated the alteration of postural equilibrium.When administered by osmotic pump in the
MIA osteoarthritis, MnL4 reduced pain, articular derangement, plasma TNF alpha levels, and protein carbonylation. The scaffold
ring was ineffective. MnL4 (10−7M) prevented the lipid peroxidation of isolated human chondrocytes when O
2
∙− was produced
by RAW 264.7. MnL4 behaves as a potent pain reliever in acute inflammatory and chronic articular pain, being its efficacy related
to antioxidant property. Therefore MnL4 appears as a novel protective compound potentially suitable for the treatment of joint
diseases.
1. Introduction
Reactive oxygen species (ROS) are by-products of cellular
metabolism and can behave as second messengers in physio-
logical conditions. However, in degenerative and inflamma-
tory diseases, ROS production is dramatically increased and
can induce cell, tissue, and organ toxicity [1]. In particular,
ROS overproduction is a typical hallmark of rheumatoid
arthritis [2, 3] and osteoarthritis [4, 5]. In addition, ROS are
involved in pain sensation [6–9].
Superoxide anion (O
2
∙−) is one of the most harmful oxi-
dant species identified in the above pathological conditions
[2]. The superoxide dismutase enzymes (SOD) can reduce
O
2
∙− toxicity. Three SOD families have been characterized:
the cytosolic Cu/Zn-SOD1, the matrix mitochondrial Mn-
SOD2, and the extracellular EC-SOD3.
The importance of ROS in joint degeneration is indicated
by the finding that EC-SOD3-deficient mice show increased
severity of collagen-induced arthritis [10]. Moreover, in
inflammatory conditions, O
2
∙− reacts with nitric oxide to
formperoxynitrite which can decrease SOD functionality [9].
In addition, Mn-SOD2 is downregulated in osteoarticular
cartilage [11, 12]. EC-SOD3 is also decreased in the cartilage of
osteoarthritic patients and in amousemodel of osteoarthritis
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[13]. Of note, decreased SOD2 and SOD3 expression precedes
the appearance of histological lesions in osteoarticular carti-
lage [14].
All these data emphasize the concept that, during inflam-
mation and degenerative arthritis, the physiological defences
against O
2
∙− are reduced, suggesting that compounds able to
decompose O
2
∙− may be pharmacological aids for the treat-
ment of articular pain.
We have described the O
2
∙− scavenging activity of some
polyamine-polycarboxylate-MnII complexes [15]. Among
tested compounds, the 4,10-dimethyl-1,4,7,10 tetraazacyclod-
odecane-1,7-diacetic acid MnII complex (MnIIMe
2
DO2A,
herein indicated as MnL4, Supplementary Material, See
Figure S1 in SupplementaryMaterial available online at http://
dx.doi.org/10.1155/2013/905360) is the most potent agent of
the series.
In a cellular environment, MnL4 (1 𝜇M–10 nM) dose-
dependently reduces O
2
∙− generated enzymatically (xan-
thine/xanthine oxidase) or by formyl-methionyl-leucyl-phe-
nylalanine- (fMLP-) activated macrophages. MnL4 (100 nM)
can cross cell membranes and significantly reduces oxidative
injury in cells exposed to O
2
∙−. Systemically administered to
mice (5–15mg kg−1 body weight), MnL4 reduces the acute
pain induced by acetic acid (writhing test). Since this anti-
inflammatory effect has been observed with both intraperi-
toneal and oral administration,MnL4 demonstrates a favour-
able pharmacokinetic profile [15]. Moreover, MnL4markedly
reduces lung inflammation, oxidative, injury, and breathing
dysfunction induced by exposure to the airborne allergen in
sensitized guinea pigs [16].
Compared with other SOD mimetics, MnL4 would have
the advantage of being a smaller, more lipophilic molecule,
capable of readily entering cells and decomposing O
2
∙− at
cytoplasmic sites of generation [17]. The present study was
therefore designed to test the action of MnL4 in rodent
models currently used to reproduce acute inflammation,
rheumatoid arthritis, or osteoarthritis. According to the high
potency of this SOD mimetic compound, we used the low
dosage 15mg kg−1.
2. Materials and Methods
2.1. Animals. Male Sprague-Dawley rats (Harlan, Varese,
Italy) weighing approximately 200–250 g at the beginning of
the experimental procedure were used for the experiments.
Four animals per cage were housed at 23 ± 1∘C under a
12 h light/dark cycle; they were fed with standard laboratory
diet and tap water ad libitum and used at least one week
after their arrival. The experimental protocol complied with
the European Community guidelines for animal care (DL
116/92, the European Communities Council Directive of
24 November 1986: 86/609/EEC) and was approved by the
animal subject reviews’ board of the University of Florence.
The ethical policy of the University of Florence complies
with the Guide for the Care and Use of Laboratory Animals
of the US National Institutes of Health (NIH Publication
no. 85-23, revised 1996; University of Florence assurance
number: A5278-01). Animals were anesthetized with 2%
isoflurane before the surgical procedures and sacrifice, which
was performed by cervical dislocation. All efforts were made
to minimize suffering and reduce the number of animals
used. Rats were randomly assigned to each experimental
group and individually habituated to handling before testing.
2.2. Drug Administration. MnL4, H
2
L4, diclofenac, ibupro-
fen, and gabapentin were dissolved in sterile saline solution.
In a first experimental set, the abovementioned compounds
were administered acutely by intraperitoneal (i.p.) injections
at the indicated doses. MnL4 and H
2
L4 dosages were chosen
on the base of previous experiments [15]; typical doses were
chosen for diclofenac, ibuprofen, and gabapentin [18–20].
In a second experimental set,MnL4was given by continu-
ous subcutaneous (s.c.) delivery using an osmotic minipump
(Alzet 2002, Palo Alto, CA, USA) implanted on the back and
filled to deliver a daily dose of 15mg kg−1 for 14 days.
The organic ligand 4,10-dimethyl-1,4,7,10-tetraazacyclod-
odecane-1,7-diacetic acid (H
2
L4) was synthesized as previ-
ously reported. This compound was isolated as trihydrochlo-
ride salt (H
2
L4⋅3HCl [15]). Its MnII complex, MnL4, was
obtained by reaction of MnSO
4
with H
2
L4⋅3HCl (1 : 1 molar
ratio) in aqueous solution at neutral pH under nitrogen
atmosphere; the MnL4 complex was then isolated as a white
solid by precipitation with an ethanol/diethyl ether 2 : 1
mixture, according to a previously described procedure [15].
The complex was further purified by recrystallization with
water/ethanol. The purity of both compounds was ascer-
tained by elemental analysis. Diclofenac, ibuprofen, gabapen-
tin, and fMLP were purchased from Sigma-Aldrich, Milan,
Italy.
2.3. Carrageenan-Induced Acute Inflammatory Pain. 100𝜇L
of carrageenan solution (Sigma-Aldrich; 1% in saline) was
injected intraplantarly into the left hindpaw.Three hours after
carrageen injection, MnL4, H
2
L4 (15mg kg−1), diclofenac,
ibuprofen (15 and 100mg kg−1), or saline was i.p. adminis-
tered and their antihyperalgesic effect was measured along
the following 45 minutes (at time 15, 30, and 45 minutes) by
the paw pressure test. Control rats received 100𝜇L of saline
solution intraplantarly and saline i.p.
2.4. Freund’s Adjuvant-Induced Inflammatory Arthritis.
Articular damage was induced by injection of complete Fre-
und’s adjuvant (CFA, Sigma-Aldrich) into the tibiotarsal joint
[21]. Briefly, the rats were slightly anesthetized by 2% iso-
flurane, the left leg skin was sterilized with 75% ethyl alcohol,
and the lateral malleolus located by palpation; then, a
28-gauge needle was inserted vertically to penetrate the
skin and turned distally for insertion into the articular
cavity at the gap between the tibiofibular and tarsal bone
until a distinct loss of resistance was felt. A volume of
50𝜇L of CFA was then injected (day 0). The paw pressure
and the incapacitance tests (see below) were performed
7 days after CFA administration. MnL4 (5 and 15mg kg−1),
H
2
Me
2
DO2A (15mg kg−1), ibuprofen (15 and 100mg kg−1),
diclofenac (15 and 100mg kg−1), or saline was i.p.
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administered. Control rats received 50𝜇L of saline solution
(day 0) in the tibiotarsal joint and saline i.p. at day 7.
2.5.Monoiodoacetate-InducedOsteoarthritis. Unilateral oste-
oarthritis was also induced by injection of monoiodoace-
tate (MIA, Sigma-Aldrich) into the tibiotarsal joint. On day
0, rats were slightly anesthetized by 2% isoflurane, the left
leg skin was sterilized with 75% ethyl alcohol, and the lateral
malleolus located by palpation; then, a 28-gauge needle
was inserted vertically to penetrate the skin and turned
distally for insertion into the articular cavity at the gap
between the tibiofibular and tarsal bone until a distinct
loss of resistance was felt. 2mg MIA in 25 𝜇L saline was
delivered into the left articular cavity. The paw pressure and
the incapacitance tests (see below) were performed at day 14.
MnL4 (15mg kg−1), H
2
Me
2
DO2A (15mg kg−1), gabapentin
(70mg kg−1), or saline was i.p. administered. Control rats
received 25 𝜇L of saline solution (day 0) in the tibiotarsal joint
and saline i.p. at day 14. To evaluate its preventive effect,MnL4
was administered by continuous s.c. infusion, from day 0 to
day 14, using the Alzet 2002 osmotic minipump (15mg kg−1
day).
2.6. Paw Pressure Test. The pain threshold in the rat was
determined with an analgesimeter (Ugo Basile, Varese, Italy)
as described [22]. Briefly, a constantly increasing pressure
was applied to a small area of the dorsal surface of the paw
using a blunt conical probe. Pressure was increased until a
vocalization or a withdrawal reflex occurred.The withdrawal
threshold was expressed in grams, the test was repeated
twice, and the mean was considered as the value for each
paw. Before starting experimental protocols, pain threshold
was evaluated and rats scoring below 50 g or over 80 g were
discarded.These limits assured a more precise determination
of mechanical withdrawal threshold in experiments aimed
to determine the effect of treatments. Mechanical pressure
application was stopped at 150 g independently of rat reflex.
Blind experiments were performed. In the saline + saline,
carrageenan + saline, CFA + saline, and MIA + saline
treated groups, recorded pressure values did not vary when
repetitively measured during the experimental session.
2.7. Incapacitance Test. Weight bearing changes were mea-
sured using an incapacitance apparatus (Linton Instrumen-
tation, UK) detecting changes in postural equilibrium after a
hind limb injury [23]. Rats were trained to stand on their hind
paws in a box with an inclined plane (65∘ from horizontal).
This box was placed above the incapacitance apparatus. This
allowed us to independently measure the weight that the
animal applied on each hind limb. The value considered for
each animal was the mean of 5 consecutive measurements.
In the absence of hind limb injury, rats applied an equal
weight on both hind limbs, indicating a postural equilibrium,
whereas an unequal distribution of the weight on hind limbs
indicated a monolateral decreased pain threshold. Data are
expressed as the difference between the weight applied on the
limb contralateral to the injury and the weight applied on the
ipsilateral one. Blind experiments were performed.
2.8. Histopathological and Biochemical Evaluations. Tissues
of rats used to study the preventive effect ofMnL4 (minipump
infused) and their controls were analyzed as follows. (a)
Legs were cut under the knee, flayed, and fixed in 4%
formaldehyde in phosphate-buffered saline (PBS) for 48 h.
Samples were then rinsed in PBS and placed in decalcifying
solution (4N formic acid in distilled water), which was
changed every 7 days until bone demineralization was com-
plete (42 days). Samples were dehydrated in graded ethanol,
embedded in paraffin wax, cut into 6 𝜇m thick sections, and
stained with hematoxylin and eosin. Histological sections
taken in the midst of the tibiotarsal joint were viewed and
photographed under a light microscope equipped with a
digital camera. (b) After sacrifice, blood was collected in
heparin-treated tubes and plasma fraction was isolated by
centrifugation. Plasmatic TNF-𝛼 levels were evaluated by
ELISA method (eBioscience, San Diego, CA, USA), using
a specific antirat polyclonal antibody. In order to obtain
detectable levels of TNF plasma samples were lyophilized
and reconstituted in 1/5 of the initial volume. Range sen-
sitivity was 11.2–2.500 pg mL−1. (c) Total plasma proteins
was quantified by bicinchoninic acid (BCA; Sigma-Aldrich)
assay. Then, 20𝜇g of each sample was denatured by 6% SDS
and derivatized by 15min incubation with 2–4 dinitrophenyl
hydrazine (DNPH; Sigma-Aldrich) at room temperature in
order to evaluate carbonylated protein evaluation. Samples
were separated on a 10% sodium dodecyl sulphate- (SDS-
) polyacrylamide gel by electrophoresis and blotted onto
nitrocellulosemembranes (BioRad,Milan, Italy).Membranes
were blocked with 5% non-fat dry milk in phosphate-
buffered saline (PBS) containing 0.1% Tween 20 (PBST)
and then incubated overnight with anti-DNPH primary
antibodies (Sigma-Aldrich; 1 : 5000 in PBST added with 5%
non-fat dry milk). After washing with PBST, the membranes
were incubated for 1 h in PBST containing the appropri-
ate horseradish peroxidase-conjugated secondary antibody
(1 : 5000; Cell Signalling, USA) and thoroughly washed [24].
The chemiluminescent substrate ECL (Pierce, USA) was
used to visualize the peroxidase-coated bands. Densitometric
analysis was performed using the free-share Scion Image 4.03
image analysis software (Scion Corp., Frederick, MD, USA).
Ponceau-stained membranes were used as loading control
[25].
2.9. Patient’s Characteristics and Isolation of Human Chon-
drocytes. Human chondrocytes used for the experiments
were isolated from 3 patients requiring arthroplasty for
degenerative disorders of the knee. Slices of articular cartilage
were obtained from a peripheral zone of the affected joint,
outside regions with macroscopic degeneration but close
to the calcified cartilage layer, after administration of an
informed consent approved by the Local Ethical Committee.
Human chondrocytes (HCs)were isolated and cultured in
Dulbecco’sModifiedEagle’sMedium (DMEM) supplemented
with 10% fetal calf serum (FCS, Gibco, Invitrogen, Italy),
2mM L-glutamine, 100 IU mL−1 penicillin, and 100𝜇g mL−1
streptomycin in 5% CO
2
atmosphere at 37∘C as described
[26].
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2.10. Human Chondrocyte Lipid Peroxidation Induced by
Stimulated RAW264.7. For the experiments, HCs at the
3rd culture passage were used in 5 separate experiments.
They were grown to 90% confluence on 6-well cell culture
plates (Corning, Italy) and starved for 18 h in serum-free
medium. The mouse leukemic monocyte macrophage cell
line (RAW 264.7) was obtained from American Type Culture
Collection (Rockville, MD, USA). RAW 264.7 were grown
in DMEM supplemented with 10% FCS, 2mM L-glutamine,
100 IUmL−1 penicillin, and 100𝜇gmL−1 streptomycin in 5%
CO
2
atmosphere at 37∘C. 72 h before experiments, cells
were detached, plated on the upper layer of polycarbonate
transwell dishes with a pore diameter of 3 𝜇m (Corning,
Italy), and starved in serum-free medium for the last 18 h.
The transwells were then placed into HCs-containing wells,
and cells were coincubated together in DMEM without
phenol red for 30min in the absence or presence of 10−7M
MnL4. Then, RAW 264.7 were activated with 10−7M fMLP
(dissolved in DMEM), while in control samples the same
volume of DMEM was added. According to previous data
[15], fMLP-activated RAW 264.7 produced a significant and
reproducible amount of O
2
∙−. The basal value of HCs lipid
peroxidation was obtained in cells not cocultured with
RAW 264.7. After 4 h, the reaction was stopped on ice; the
upper layer with RAW 264.7 was removed. HCs were scraped
in 1mL of cold PBS, and the cell suspension was used to
measure the thiobarbituric acid reactive substances (TBARS),
assumed as a marker of cell oxidative injury. Briefly, the
suspensions were mixed with 4 mL thiobarbituric acid
(36mM in acetic acid/sodium acetate, adjusted to pH 4 with
NaOH) and boiled for 1 h. After cooling on ice, the mixture
was centrifuged at 5000×g for 10min and the absorbance
of the supernatant was spectrophotometrically evaluated at
the 532 nm wavelength against a standard curve of 1,1,3,3-
tetramethoxypropane. Protein concentration in the samples
was determined using the Coomassie protein assay (Pierce,
Rockford, IL, USA). TBARS values were expressed as 𝜇mol
mg−1 of proteins. All reagents used were of the highest purity
grade.
2.11. Statistical Analysis. All experiments were evaluated
blind. Results were expressed as the means ± s.e.m. Statistical
analysis of differences among the experimental groups was
performed using one-way ANOVA followed by Student-
Newman-Keuls post hoc test. A P value ≤ 0.05 was considered
significant.
3. Results
3.1. Effects of MnL4 on Carrageenan-Induced Acute Inflam-
matory Pain. Three hours after the administration of car-
rageenan, all inflammatory signs were observed (paw
swelling hyperaemia and hyperalgesia).The paw pressure test
was used to measure pain. In ipsilateral paw (carrageenan +
saline), the mechanical withdrawal threshold was signifi-
cantly decreased as compared to the controlateral paw and
control animals (saline + saline, Figure 1) and remained to
the same value for at least 1 h.MnL4 (15mg kg−1) significantly
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Figure 1: Effect of MnL4, H
2
L4, ibuprofen, and diclofenac on
carrageenan-induced acute inflammatory pain. Carrageenan (Car,
1%, 100𝜇L) was injected in the left posterior sole 3 hours before
pain evaluation by the paw pressure test. Molecules or saline was
administered i.p. at time 0 and measures were performed at time 15,
30, and 45min. Values are the mean ± s.e.m. of 6 animals. ∗𝑃 < 0.05
versus the ipsilateral paw of carrageenan + saline group.
increased mechanical withdrawal threshold in the ipsilateral
(carrageenan + MnL4) paw 30min after its i.p. administra-
tion (Figure 1), but not modify the contralateral one (data not
shown). Neither H
2
L4 (Figure 1), nor ibuprofen or diclofenac
(not shown) at the same dosage ofMnL4were active, whereas
ibuprofen and diclofenac at 100mg kg−1 i.p. were effective
(Figure 1).
3.2. Effects of MnL4 on CFA-Induced Inflammatory Arthritis.
With the aim of testing the pharmacological activity of
MnL4 in articular inflammatory damage resembling human
rheumatoid arthritis [27], the SOD mimetic compound
was evaluated in the CFA-model. The pain threshold was
measured 7 days after intra-articular CFA injection by paw
pressure and incapacitance tests. The mechanical withdrawal
threshold in ipsilateral- (CFA + saline) treated pawwas signi-
ficantly reduced as compared to the controlateral paw and
control animals (saline + saline). MnL4 (15mg kg−1), 15
minutes after i.p. administration, increased the withdrawal
threshold and was still effective after 45 minutes while at
the dose of 5mg kg−1 was effective 30min after adminis-
tration (Figure 2). Ibuprofen and diclofenac at 100mgkg−1
i.p. were also active (Figure 2). H
2
L4 (Figure 2), ibuprofen,
or diclofenac (not shown) was ineffective at 15mgkg−1.
Moreover,MnL4 significantly reduced hindpawunbalance in
a time-dependentmanner, being particularly effective 30min
after i.p. injection (Table 1).
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Figure 2: Effect of MnL4, H
2
L4, ibuprofen, and diclofenac on com-
plete Freund’s adjuvant-induced inflammatory arthritis. Complete
Freund’s adjuvant (CFA, 50 𝜇L) was injected in the left posterior
tibiotarsal articulation 7 days before the pain evaluation by the
paw pressure test. Molecules or saline was administered i.p. at the
indicated doses at time 0 and measures were performed at time
15, 30, 45, and 60min. Values are the mean ± s.e.m. of 6 animals.
∗
𝑃 < 0.05 and ∗∗𝑃 < 0.01 versus the ipsilateral paw of CFA + saline
group.
3.3. Effect of MnL4 onMIA-Induced Osteoarthritis. The effec-
tiveness of MnL4 was evaluated in the rat unilateral osteoar-
thritis induced by MIA according to two different protocols:
acute i.p. administration (15mg kg−1, 15–60 minutes before
the test) or continuous subcutaneous infusion by osmotic
minipumps (15mg kg−1 day−1 for 14 days). Fourteen days
after MIA, the weight tolerated on the ipsilateral paw (MIA +
saline) was significantly reduced as compared to the contro-
lateral paw and control animals (saline + saline, Figure 3).
MnL4 (15mg kg−1), 15 minutes after i.p. administration,
increased the withdrawal threshold and was still effective
after 60 minutes. At the same dosage, H
2
L4 was ineffective
(Figure 3). Gabapentin (70mg kg−1) showed a higher effec-
tiveness than MnL4 30min after administration, but was
similarly active at the other times (Figure 3).
Moreover, MnL4 significantly reduced hind limb weight
bearing alterations, being particularly effective 30min after
i.p. injection (Table 1).
MnL4 (15mg kg−1 day−1) was also effective when contin-
uously administered by s.c. route for 14 days (Figure 4(a)).
This functional effect was accompanied by a substantial
improvement of joint histopathology. Figure 4(b) shows rep-
resentative pictures of hematoxylin-eosin-stained longitudi-
nal sections of tibiotarsal joints in the different experimental
conditions: 14 days after injection,MIA caused intra-articular
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Figure 3: Effect of MnL4,H
2
L4, and gabapentin (acutely adminis-
tered) on monoiodoacetate- (MIA-) induced unilateral osteoarthri-
tis. MIA (2mg/25 𝜇L) was injected in the left posterior tibiotarsal
articulation 14 days before pain evaluation by the paw pressure test.
Molecules or saline was administered i.p. at time 0 and measures
were performed at time 15, 30, 45, and 60min. Values are themean ±
s.e.m. of 6 animals. ∗𝑃 < 0.05 versus the ipsilateral paw of MIA +
saline group, ∧𝑃 < 0.05 versus MIA + MnL4 at the same time.
fibrin accumulation and extensive degeneration of the articu-
lar cartilage, that is, overall thinning, ulceration, and scarring.
These changes resulted in a marked reduction of the intra-
articular space compared to the normal joint (contralateral,
control). Continuous s.c. administration of MnL4 prevented
the appearance of these cartilage abnormalities and improved
the intra-articular space. This beneficial effect of long-term
MnL4 treatment was confirmed by the dosage of TNF-𝛼
plasma levels. As reported in Table 2, TNF-𝛼was significantly
increased in MIA + saline-treated rats at day 14 compared
to naı¨ve animals; MnL4 completely prevented MIA-induced
TNF-𝛼 elevation. Moreover, in MIA + saline-treated rats,
systemic oxidative damage was also present, as evaluated by
the carbonylation of plasma proteins. In fact, on the 14th day,
plasma-carbonylated proteins increased up to twice the basal
level of naive animals (5.9 ± 0.29; densitometric arbitrary
units). MnL4 (15mg kg−1 day−1) significantly reduced this
oxidation parameter (Figure 5).
3.4. Effect of MnL4 on Lipid Peroxidation in Human-Cultured
Chondrocytes. In order to study the effect of MnL4 on an
ROS attack in HCs, we performed experiments in a coculture
system of HCs and mouse leukaemic monocyte macrophage
cells (RAW 264.7). This experimental set allowed us to study
the effect of RAW 264.7-produced O
2
∙− on HCs lipid per-
oxidation. In basal conditions (without coculture with RAW
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Table 1: Effect of MnL4 on hind limb weight bearing alterations induced by CFA or MIA.
Treatment ΔWeight (g) (contralateral minus ipsilateral paw)
0min 15min 30min 45min 60min
Control (saline + saline) 5.2 ± 2.3 3.1 ± 1.9 3.8 ± 2.5 4.2 ± 3.0 6.3 ± 3.1
CFA + 15mg kg−1 MnL4 58.8 ± 1.6∧∧ 37.9 ± 2.1∗ 28.7 ± 1.9∗∗ 34.8 ± 2.0∗ 40.6 ± 2.3∗
Control (saline + saline) 3.2 ± 1.2 −2.3 ± 2.1 1.5 ± 3.1 −3.0 ± 2.8 3.8 ± 2.5
MIA + 15mg kg−1 MnL4 61.3 ± 2.3∧∧ 30.2 ± 3.1∗ 20.1 ± 3.6∗∗ 40.3 ± 1.1∗ 55.3 ± 2.9
Hind limb weight bearing alterations were evaluated in rats by incapacitance test. In the absence of hind limb injury, rats applied an equal weight on both hind
limbs, whereas an unequal distribution of the weight on hind limbs indicated a monolateral decreased pain threshold. CFA was injected 7 days before the test,
MnL4 was acutely i.p. administered at time 0min; MIA was injected 14 days before the test, MnL4 was acutely i.p. administered at time 0min.
∧∧
𝑃 < 0.01 in respect to control (saline + saline) group; ∗∗𝑃 < 0.01 and ∗𝑃 < 0.05 with respect to the 0min value of the same treatment.
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Figure 4: Effect ofMnL4 (continuously infused for 15 days) onmonoiodoacetate- (MIA-) induced unilateral osteoarthritis.MIA (2mg/25 𝜇L)
was injected in the left posterior tibiotarsal articulation 14 days before the pain evaluation by the paw pressure test. At day 0, a minipump
containing MnL4 solution (15mg kg−1 day) was implanted on the back of MnL4-treated rats. Values are the mean ± s.e.m. of 5 animals.
Panel (a): pain behavior; ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01 versus MIA + saline. Panel (b): effect of MnL4 (continuously infused for 15 days) on
tibiotarsal articulation histopathology on MIA-induced osteoarthritis. Hematoxilin and eosin staining of longitudinal section of tibiotarsal
joint. Pictures are representative of histological preparations from 5 animals per group. Bars = 100𝜇m.
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Figure 5: Effect of MnL4 (15mg kg−1 continuously infused for 15 days) on plasma oxidation levels 14 days after MIA injection (2mg/25𝜇L
in the left posterior tibiotarsal articulation on day 0). Immunoblot analysis was performed after a reaction with dinitrophenylhydrazine.
Densitometric analysis and representative Western blot are shown. Ponceau-stained membranes were used as loading control. Each value
represents the mean of 4 biological samples. ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01 versus control rats; ∘𝑃 < 0.05 versus MIA + saline treatment.
Table 2: TNF𝛼 plasma levels in control, MIA- and MnL4 + MIA-
treated rats.
Control (saline + saline) Saline + MIA MnL4 + MIA
pg/mL 5.37 ± 1.77 16.86 ± 2.02∗ 4.75 ± 1.69
Monoiodoacetate (MIA, 2mg/25𝜇L) or saline was injected in the left
posterior tibiotarsal articulation 14 days before the test. At day 0, aminipump
containing MnL4 solution (15mg kg−1 day) was implanted on the back of
MnL4 +MIA-treated rats. TNF𝛼 levels were measured in plasma samples by
ELISA.
∗
𝑃 < 0.01 versus saline + saline and the MnL4 + MIA groups.
264.7), membrane lipid peroxidation of HCs (expressed as
TBARS)was 1.24±0.14 𝜇mol mg−1 of proteins.This valuewas
not significantly modified when HCs were incubated with
unstimulated RAW 264.7 (1.65±0.18 𝜇mol mg−1 of proteins,
control) but was markedly and significantly increased up to
3.0 ± 0.54 𝜇mol mg−1 of proteins when RAW 264.7 were
stimulated with 10−7M fMLP (Figure 6). When cells were
preincubated with 10−7M MnL4, lipid peroxidation was
totally prevented.
4. Discussion
Inflammatory conditions (and in particular, joint diseases)
induce an increase in ROS which have a deleterious role in
erosion, osteoarticular degeneration, and pain. Conversely,
ROS increase inflammatory mediators [28]. ROS are also
implicated in persistent pain behavior as already demon-
strated by several authors [25, 29, 30]. Therefore, molecules
able to reduce O
2
∙− can be used to reduce pain and inflam-
mation.
Following this line of reasoning, extractive or recom-
binant SOD seems to be the most valid choice for such a
targeted therapeutic approach [31]. However, its clinical use
is hampered by multiple factors, including instability, limited
cellular accessibility, immunogenicity, short half-life, and
high production costs [32, 33]. Because of these limitations,
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Figure 6: Effect of 10−7MMnL4 on the lipid peroxidation (TBARS)
induced by superoxide anion in human chondrocytes. Human
chondrocytes were coincubated with RAW 264.7 with or without
10
−7M MnL4. RAW 264.7 were activated by 10−7M fMLP for 4 h
to produce superoxide anions. Values are expressed as percentage of
control values (human chondrocytes coincubatedwith unstimulated
RAW 264.7). TBARS in control value was 1.65 ± 0.18 𝜇moles mg−1
of total proteins. Each value represents the mean of 5 experiments,
performed using chondrocytes isolated from 3 patients. ∗𝑃 < 0.05
versus all other conditions.
SODmimetic compounds have been proposed as appropriate
strategies in many degenerative pathological conditions [32],
and pharmacological research has highlighted lowmolecular
weight compounds, such as the antioxidant Tempol [34] and
the MnII chelates with organic scaffolds [17, 35], capable of
catalyzing O
2
∙− decomposition like authentic SOD. Tempol
and MnII complexes with pentaazamacrocycles, salen-, and
porphyrin-based scaffolds have been reported to reduce
inflammation and pain in different animalmodels of articular
diseases [9, 34, 36, 37]. The SOD mimetic compound MnL4
has already been characterized as a membrane-permeable,
highly effective scavenger compound [15], possessing anti-
inflammatory properties in a model of allergic asthma [16].
Therefore, we studied it using a panel of in vivo rat models of
articular pain induced by acute and chronic inflammation.
Intra-articular injection of MIA provides a rodent model
of monolateral osteoarthritis with features resembling those
seen clinically. These include synovial thickening, loss of car-
tilage, formation of osteophytes, and eventual fibrillation of
cartilage [18, 38, 39]. Morphological alterations are associated
with a persistent inflammatory pain which, starting from
the 14th day after MIA injection, possesses a neuropathic
component [20]. Nonsteroidal anti-inflammatory drugs such
as diclofenac can reduce MIA-dependent pain during the
first inflammatory phase, but they are ineffective in the
degenerative neuropathic phase [40], while gabapentin, an
antiepileptic molecule widely used to treat neuropathic pain
in adult patients [41], is effective [20].
In the MIA model, acutely administered MnL4
(15mg kg−1) causes a prolonged (60min) reduction of
pain sensitivity during the phase when the neuropathic
component prevails over the inflammatory one and its
efficacy is quite similar to that of gabapentin administered at
typical dosage [20]. Its parent compound, H
2
L4, which lacks
ROS-scavenging effects, is totally ineffective.
Although we injected MIA in tibiotarsal articulation,
several characteristics of our model resemble those observed
after MIA knee injection. Indeed, after 14 days from MIA
injection, the neuropathic component of pain predominates
as demonstrated by the high effectiveness of gabapentin.
Moreover, the histological analysis confirms a degeneration
pattern of the tibiotarsal joint similar to that described for
knee [23, 42]. The performed model permits us to directly
compare MnL4 as pain reliever in MIA and CFA.
In the same osteoarthritis model, MnL4, continuously
infused by an osmotic pump (chronic administration),
increases the pain threshold and ameliorates tibiotarsal joint
histopathological parameters. Moreover, in blood samples
obtained at the same stage of joint degenerative changes,
the SODmimetic compound prevents the significant, TNF-𝛼
increase induced by MIA and reduces protein carbonylation.
The proinflammatory cytokine, TNF-𝛼, is a critical mediator
in osteoarthritis and rheumatic disease. Its serum level is
linearly related to disease activity clinical score in patients
with rheumatoid arthritis, and it has been proposed as clinical
marker of this pathology [43]. TNF-𝛼 upregulation is a
consequence of NF𝜅B nuclear translocation which can be
due to the ROS-activated intracellular signaling cascade [44].
Carbonylation of proteins is an irreversible oxidative damage.
Carbonyl groups are introduced into protein side chains by
a site-specific mechanism often leading to a loss of protein
function. It is considered a widespread indicator of severe
oxidative damage and disease-derived protein dysfunction
[45]; its increase has been described in the plasma of human
subject affected by systemic rheumatic diseases [46].
CFA-induced inflammatory arthritis in rats presents
similar features to rheumatoid arthritis [27]. CFA-induced
inflammatory arthritis starts between the 3rd and 7th days
after inoculation; at this time, the pain threshold is sig-
nificantly decreased [47], while sensory neuron firing is
increased [48] leading to changes in gene expression and sen-
sitization of the nervous system. These functional alterations
contribute to the pain associated with joint injuries [49].
Seven days after CFA injection, 15mg kg−1 MnL4, acutely
administered before the behavioral tests, increases the pain
threshold for at least 45min and prevents the hind limb
weight bearing alterations whereas the scaffold congener of
MnL4 is totally ineffective.
Since acute inflammation occurs at the initial stage of
articular diseases, we tested MnL4 in carrageenan-induced
paw acute edema. In this condition, 30min after admin-
istration, MnL4 enhances the pain threshold, decreasing
mechanical hypersensitivity by about 50%. However, the
effectiveness of MnL4 in this model is short lasting. At the
same dosage (15mg kg−1), the well-known anti-inflammatory
NSAIDs ibuprofen and diclofenac are ineffective, being
their anti-inflammatory activity observed at higher dosages
(100mg kg−1) currently used in animal tests [18, 19].
Many of the effects of MnL4 are in agreement with the
antioxidant property of the compound [15, 16]: accumulating
evidence indicates that the production of ROS is increased in
the nociceptive system during persistent inflammatory and
neuropathic pain [50]. Since ROS have also been implicated
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in chondrocyte degeneration and death [4], we tested MnL4
activity against the oxidative stress induced by O
2
∙− in
isolated human chondrocytes. According to previous data
of our laboratory on reproducibility and effectiveness of
RAW 264-7 in producing O
2
∙− after fMLP stimulation [15],
we coincubated human chondrocytes with RAW 264-7.
This experimental condition simulates an ROS attack on
chondrocytes by infiltrating inflammatory cells. MnL4 at
10
−7M can totally prevent lipid peroxidation, suggesting an
important contribution to joint protection.
In conclusion, MnL4 behaves as a potent pain reliever
compound both in arthritis models and, to a lesser extent, in
acute inflammation. This effect is not related to a direct inhi-
bition of cyclooxygenase enzymes as already described [15]
but, conceivably, related to the SOD mimetic property of the
molecule as also demonstrated on HCs. The mechanism by
whichMnL4 acts after chronic and acute administrationmay
be somewhat different. Namely, chronically administered
MnL4 may prevent tissue degenerative alterations induced
by the oxidative stress and reduce a persistent inflammatory
pain via a direct antioxidant mechanism; while in acute
administration, it may decrease the nociceptive nervous
fiber activation induced by the local production of ROS
[28, 50]. Given these properties and the low toxicity of the
molecule, MnL4 is a novel compound potentially suited for
the treatment of inflammatory and neuropathic pain.
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